188 related articles for article (PubMed ID: 30111844)
61. Effects of CD20 antibodies and kinase inhibitors on B-cell receptor signalling and survival of chronic lymphocytic leukaemia cells.
Cavallini C; Galasso M; Pozza ED; Chignola R; Lovato O; Dando I; Romanelli MG; Krampera M; Pizzolo G; Donadelli M; Scupoli MT
Br J Haematol; 2021 Jan; 192(2):333-342. PubMed ID: 33216963
[TBL] [Abstract][Full Text] [Related]
62. CLL cells respond to B-Cell receptor stimulation with a microRNA/mRNA signature associated with MYC activation and cell cycle progression.
Pede V; Rombout A; Vermeire J; Naessens E; Mestdagh P; Robberecht N; Vanderstraeten H; Van Roy N; Vandesompele J; Speleman F; Philippé J; Verhasselt B
PLoS One; 2013; 8(4):e60275. PubMed ID: 23560086
[TBL] [Abstract][Full Text] [Related]
63. Immune recovery after fludarabine-cyclophosphamide-rituximab treatment in B-chronic lymphocytic leukemia: implication for maintenance immunotherapy.
Ysebaert L; Gross E; Kühlein E; Blanc A; Corre J; Fournié JJ; Laurent G; Quillet-Mary A
Leukemia; 2010 Jul; 24(7):1310-6. PubMed ID: 20463751
[TBL] [Abstract][Full Text] [Related]
64. Inactivation of TP53 correlates with disease progression and low miR-34a expression in previously treated chronic lymphocytic leukemia patients.
Dufour A; Palermo G; Zellmeier E; Mellert G; Duchateau-Nguyen G; Schneider S; Benthaus T; Kakadia PM; Spiekermann K; Hiddemann W; Braess J; Truong S; Patten N; Wu L; Lohmann S; Dornan D; GuhaThakurta D; Yeh RF; Salogub G; Solal-Celigny P; Dmoszynska A; Robak T; Montillo M; Catalano J; Geisler CH; Weisser M; Bohlander SK
Blood; 2013 May; 121(18):3650-7. PubMed ID: 23525797
[TBL] [Abstract][Full Text] [Related]
65. Fludarabine, Cyclophosphamide and Rituximab: an effective chemoimmunotherapy combination with high remission rates for chronic lymphocytic leukaemia.
Hayat A; McGuckin S; Conneally E; Brown PV; McCann SR; Lawler M; Quinn F; Delaney E; O'Rourke P; Liptrot S; O'Brien D; Vandenberghe E
Ir J Med Sci; 2009 Dec; 178(4):441-6. PubMed ID: 19495836
[TBL] [Abstract][Full Text] [Related]
66. [Treatment of chronic lymphocytic leukemia with regimen of fludarabine, cyclophosphamide and rituximab].
Gu WJ; Xu W; Qian SX; Wu YJ; Hong M; Chen LJ; Wu HX; Lu H; Qiu HX; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):938-42. PubMed ID: 18718095
[TBL] [Abstract][Full Text] [Related]
67. Efficacy and safety of front-line therapy with fludarabine-cyclophosphamide-rituximab regimen for chronic lymphocytic leukemia outside clinical trials: the Israeli CLL Study Group experience.
Herishanu Y; Goldschmidt N; Bairey O; Ruchlemer R; Fineman R; Rahimi-Levene N; Shvidel L; Tadmor T; Ariel A; Braester A; Shapiro M; Joffe E; Polliack A;
Haematologica; 2015 May; 100(5):662-9. PubMed ID: 25661442
[TBL] [Abstract][Full Text] [Related]
68. Risk adjusted therapy in chronic lymphocytic leukemia: a phase II cancer trials Ireland (CTRIAL-IE [ICORG 07-01]) study of fludarabine, cyclophosphamide, and rituximab therapy evaluating response adapted, abbreviated frontline therapy with FCR in non-del(17p) CLL.
Appleby N; O'Brien D; Quinn FM; Smyth L; Kelly J; Parker I; Scott K; Cahill MR; Crotty G; Enright H; Hennessy B; Hodgson A; Leahy M; O'Leary H; O'Dwyer M; Hayat A; Vandenberghe EA
Leuk Lymphoma; 2018 Jun; 59(6):1338-1347. PubMed ID: 28925785
[TBL] [Abstract][Full Text] [Related]
69. [New perspectives in the evolution of prognosis and treatment of chronic lymphocytic leukaemia].
Telek B; Rejto L; Kiss A; Méhes L; Batár P; Udvardy M
Orv Hetil; 2004 Aug; 145(35):1795-800. PubMed ID: 15493222
[TBL] [Abstract][Full Text] [Related]
70. Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM).
González-Rincón J; Garcia-Vela JA; Gómez S; Fernández-Cuevas B; Nova-Gurumeta S; Pérez-Sanz N; Alcoceba M; González M; Anguita E; López-Jiménez J; González-Barca E; Yáñez L; Pérez-Persona E; de la Serna J; Fernández-Zarzoso M; Deben G; Peñalver FJ; Fernández MC; de Oteyza JP; Andreu MÁ; Ruíz-Guinaldo MÁ; Paz-Arias R; García-Malo MD; Recasens V; Collado R; Córdoba R; Navarro-Matilla B; Sánchez-Beato M; García-Marco JA
PLoS One; 2021; 16(9):e0257353. PubMed ID: 34506616
[TBL] [Abstract][Full Text] [Related]
71. Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab.
Fink AM; Böttcher S; Ritgen M; Fischer K; Pflug N; Eichhorst B; Wendtner CM; Winkler D; Bühler A; Zenz T; Staib P; Mayer J; Hensel M; Hopfinger G; Wenger M; Fingerle-Rowson G; Döhner H; Kneba M; Stilgenbauer S; Busch R; Hallek M
Leukemia; 2013 Sep; 27(9):1949-52. PubMed ID: 23787395
[No Abstract] [Full Text] [Related]
72. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia.
Thompson PA; Tam CS; O'Brien SM; Wierda WG; Stingo F; Plunkett W; Smith SC; Kantarjian HM; Freireich EJ; Keating MJ
Blood; 2016 Jan; 127(3):303-9. PubMed ID: 26492934
[TBL] [Abstract][Full Text] [Related]
73. Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL.
Badoux XC; Keating MJ; Wang X; O'Brien SM; Ferrajoli A; Faderl S; Burger J; Koller C; Lerner S; Kantarjian H; Wierda WG
Blood; 2011 Mar; 117(11):3016-24. PubMed ID: 21245487
[TBL] [Abstract][Full Text] [Related]
74. Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia.
Letestu R; Dahmani A; Boubaya M; Baseggio L; Campos L; Chatelain B; Debliquis A; Drénou B; Jacob MC; Legac E; Le Garff-Tavernier M; Lhoumeau AC; Quiney C; Robillard N; Ticchioni M; Aanei C; Katsahian S; Delepine R; Vaudaux S; Rouillé V; Béné MC; Dartigeas C; Van Den Neste E; Leprêtre S; Feugier P; Cartron G; Leblond V; Lévy V; Cymbalista F;
Leukemia; 2021 Jun; 35(6):1597-1609. PubMed ID: 32934355
[TBL] [Abstract][Full Text] [Related]
75. SLAMF receptors negatively regulate B cell receptor signaling in chronic lymphocytic leukemia via recruitment of prohibitin-2.
von Wenserski L; Schultheiß C; Bolz S; Schliffke S; Simnica D; Willscher E; Gerull H; Wolters-Eisfeld G; Riecken K; Fehse B; Altfeld M; Nollau P; Binder M
Leukemia; 2021 Apr; 35(4):1073-1086. PubMed ID: 32826957
[TBL] [Abstract][Full Text] [Related]
76. Ibrutinib downregulates a subset of miRNA leading to upregulation of tumor suppressors and inhibition of cell proliferation in chronic lymphocytic leukemia.
Saleh LM; Wang W; Herman SE; Saba NS; Anastas V; Barber E; Corrigan-Cummins M; Farooqui M; Sun C; Sarasua SM; Zhao Z; Abousamra NK; Elbaz O; Abdelghaffar HA; Wiestner A; Calvo KR
Leukemia; 2017 Feb; 31(2):340-349. PubMed ID: 27431016
[TBL] [Abstract][Full Text] [Related]
77. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.
Byrd JC; Gribben JG; Peterson BL; Grever MR; Lozanski G; Lucas DM; Lampson B; Larson RA; Caligiuri MA; Heerema NA
J Clin Oncol; 2006 Jan; 24(3):437-43. PubMed ID: 16344317
[TBL] [Abstract][Full Text] [Related]
78. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.
Keating MJ; O'Brien S; Albitar M; Lerner S; Plunkett W; Giles F; Andreeff M; Cortes J; Faderl S; Thomas D; Koller C; Wierda W; Detry MA; Lynn A; Kantarjian H
J Clin Oncol; 2005 Jun; 23(18):4079-88. PubMed ID: 15767648
[TBL] [Abstract][Full Text] [Related]
79. FOXP1 and BCL2 show similar immunoenzymatic pattern in bone marrow trephines of chronic lymphocytic leukemia patients.
Korać P; Vintar MG; Ajduković R; Kardum Paro MM; Jaksić B; Dominis M
Appl Immunohistochem Mol Morphol; 2009 Dec; 17(6):500-4. PubMed ID: 19417623
[TBL] [Abstract][Full Text] [Related]
80. Outcomes of second-line treatment after fludarabine cyclophosphamide and rituximab in patients with chronic lymphocytic leukemia outside clinical trials.
Joffe E; Goldschmidt N; Bairey O; Fineman R; Ruchlemer R; Rahimi-Levene N; Shvidel L; Greenbaum U; Aviv A; Tadmor T; Braester A; Arad A; Polliack A; Herishanu Y;
Eur J Haematol; 2018 Sep; 101(3):399-406. PubMed ID: 29949186
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
